title: Interleukin-12 antagonist activity of mouse interleukin-12 p40 homodimer in vitro and in vivo.
abstract: Mo(p40)2 is a potent IL-12 antagonist that interacts strongly with the beta 1 subunit of the IL-12R to block binding of moIL-12 to the high-affinity mouse IL-12R. Mo(p40)2, alone or in synergy with the 2B5 mAb specific for the moIL-12 heterodimer, blocked IL-12-induced responses in vitro, Mo(p40)2 was thus used alone or with 2B5 mAb to examine the role of IL-12 in vivo, Mo(p40)2 caused a dose-dependent inhibition of both the rise in serum IFN-gamma levels in mice injected with endotoxin and the Th1-like response to immunization with KLH. Treatment with mo(p40)2 plus 2B5 anti-moIL-12 mAb also suppressed DTH responses to methylated bovine serum albumin but not specific allogeneic CTL responses in vivo. In each of these models, responses seen in mice treated with mo(p40)2 +/- 2B5 anti-moIL-12 mAb were similar to those observed in IL-12 knockout mice. Thus, mo(p40)2 can act as a potent IL-12 antagonist in vivo, as well as in vitro, and is currently being used to investigate the role of IL-12 in the pathogenesis of some Th1-associated autoimmune disorders in mice.
authors.affiliation: Department of Inflammation/Autoimmune Diseases, Hoffmann-La Roche Inc., Nutley, New Jersey 07110, USA.
authors.forename: M K
authors.initials: MK
authors.lastname: Gately
authors.forename: D M
authors.initials: DM
authors.lastname: Carvajal
authors.forename: S E
authors.initials: SE
authors.lastname: Connaughton
authors.forename: S
authors.initials: S
authors.lastname: Gillessen
authors.forename: R R
authors.initials: RR
authors.lastname: Warrier
authors.forename: K D
authors.initials: KD
authors.lastname: Kolinsky
authors.forename: V L
authors.initials: VL
authors.lastname: Wilkinson
authors.forename: C M
authors.initials: CM
authors.lastname: Dwyer
authors.forename: G F
authors.initials: GF
authors.lastname: Higgins
authors.forename: F J
authors.initials: FJ
authors.lastname: Podlaski
authors.forename: D A
authors.initials: DA
authors.lastname: Faherty
authors.forename: P C
authors.initials: PC
authors.lastname: Familletti
authors.forename: A S
authors.initials: AS
authors.lastname: Stern
authors.forename: D H
authors.initials: DH
authors.lastname: Presky
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D016466:CHO Cells; D006224:Cricetinae; D003602:Cytotoxicity, Immunologic; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007371:Interferon-gamma / Q000096:biosynthesis; D018664:Interleukin-12 / Q000037:antagonists & inhibitors* / Q000737:chemistry; D008198:Lymph Nodes / Q000166:cytology / Q000276:immunology; D008213:Lymphocyte Activation / Q000187:drug effects; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008970:Molecular Weight; D018123:Receptors, Interleukin / Q000378:metabolism; D053707:Receptors, Interleukin-12; D011994:Recombinant Proteins; D013329:Structure-Activity Relationship; D018417:Th1 Cells / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D018123:Receptors, Interleukin; D053707:Receptors, Interleukin-12; D011994:Recombinant Proteins; D018664:Interleukin-12; D007371:Interferon-gamma